Armondo López-Guillermo

18PUBLICATIONS
112CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)PharmacogenomicsHaematological tumoursRegenerative medicine (incl. stem cells)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Oct 24, 2025
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.

Dejan Juric, Daniel Anderson, Afshin Dowlati

|Jun 20, 2024
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.

Beatriz Rey-Búa, Carlos Grande, José J Sánchez Blanco

|Apr 10, 2024
Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112).

Juan-Manuel Sancho, Pau Abrisqueta, Abhijeet Kumar

|Oct 31, 2023
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.

Núria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego

|Jul 24, 2023
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.

A Martín García-Sancho, M Baile, G Rodríguez

|Jun 30, 2023
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.

Ana Muntañola, María Teresa Villalobos, Sonia González-Villambrosia

Pageof 3

Frequent Collaborators

9 joint publications

Pablo Mozas

7 joint publications

Julio Delgado

7 joint publications

Laura Magnano

7 joint publications

Elías Campo